株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:片頭痛 - 現在/将来の主要企業

PharmaPoint: Migraine - Current and Future Players

発行 GlobalData 商品コード 299717
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:片頭痛 - 現在/将来の主要企業 PharmaPoint: Migraine - Current and Future Players
出版日: 2014年03月31日 ページ情報: 英文 54 Pages
概要

当レポートでは、急速に成長している片頭痛の治療薬市場について取り上げ、新規参入を含めた競合情勢に焦点を当てて、主要企業に関する最新情報と詳細な分析を提供し、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因・障壁 - 世界の問題点

第4章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • GlaxoSmithKline
    • AstraZeneca
    • Merck
    • Vernalis
    • Almirall
    • Pfizer
    • Zogenix
    • NuPathe
    • Allergan
    • RedHill Biopharma
    • OptiNose
    • CoLucid Pharmaceuticals
    • SUDA
    • Revance Therapeutics
    • NeurAxon

第5章 付録

図表

目次
Product Code: GDHC1031FPR

GlobalData has released its pharma report, "PharmaPoint: Migraine - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Migraine
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Migraine market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Migraine market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. GlaxoSmithKline
    • 4.3.2. AstraZeneca
    • 4.3.3. Merck
    • 4.3.4. Vernalis
    • 4.3.5. Almirall
    • 4.3.6. Pfizer
    • 4.3.7. Zogenix
    • 4.3.8. NuPathe
    • 4.3.9. Allergan
    • 4.3.10. RedHill Biopharma
    • 4.3.11. OptiNose
    • 4.3.12. CoLucid Pharmaceuticals
    • 4.3.13. SUDA
    • 4.3.14. Revance Therapeutics
    • 4.3.15. NeurAxon

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed Migraine Patients
    • 5.4.2. Percent Drug-treated Patients
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Generic Erosion
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. Survey of Prescribing Physicians
  • 5.7. About the Authors
    • 5.7.1. Author
    • 5.7.2. Reviewer
    • 5.7.3. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Migraine, 2012-2023
  • Table 2: Migraine Market - Drivers and Barriers, 2012-2023
  • Table 3: Key Companies in the Migraine Market, 2013
  • Table 4: GSK's Migraine Portfolio Assessment, 2013
  • Table 5: GSK SWOT Analysis, 2013
  • Table 6: AstraZeneca's Migraine Portfolio Assessment, 2013
  • Table 7: AstraZeneca SWOT Analysis, 2013
  • Table 8: Merck's Migraine Portfolio Assessment, 2013
  • Table 9: Merck SWOT Analysis, 2013
  • Table 10: Vernalis' Migraine Portfolio Assessment, 2013
  • Table 11: Vernalis SWOT Analysis, 2013
  • Table 12: Almirall's Migraine Portfolio Assessment, 2013
  • Table 13: Almirall SWOT Analysis, 2013
  • Table 14: Pfizer's Migraine Portfolio Assessment, 2013
  • Table 15: Pfizer SWOT Analysis, 2013
  • Table 16: Zogenix's Migraine Portfolio Assessment, 2013
  • Table 17: Zogenix SWOT Analysis, 2013
  • Table 18: NuPathe's Migraine Portfolio Assessment, 2013
  • Table 19: NuPathe SWOT Analysis, 2013
  • Table 20: Allergan's Migraine Portfolio Assessment, 2013
  • Table 21: Allergan SWOT Analysis, 2013
  • Table 22: RedHill's Migraine Portfolio Assessment, 2013
  • Table 23: RedHill SWOT Analysis, 2013
  • Table 24: OptiNose's Migraine Portfolio Assessment, 2013
  • Table 25: OptiNose SWOT Analysis, 2013
  • Table 26: CoLucid Pharmaceuticals' Migraine Portfolio Assessment, 2013
  • Table 27: CoLucid Pharmaceuticals SWOT Analysis, 2013
  • Table 28: SUDA's Migraine Portfolio Assessment, 2013
  • Table 29: SUDA SWOT Analysis, 2013
  • Table 30: Revance Therapeutics' Migraine Portfolio Assessment, 2013
  • Table 31: Revance Therapeutics SWOT Analysis, 2013
  • Table 32: NeurAxon's Migraine Portfolio Assessment, 2013
  • Table 33: NeurAxon SWOT Analysis, 2013
  • Table 34: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Migraine by Region, 2012-2023
  • Figure 2: Company Portfolio Gap Analysis in Migraine, 2012-2023
Back to Top